HALOZYME THERAPEUTICS, INC. (HALO) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $208.97M; Long-term Debt, Excluding Current MaturitiesUSD $1.94B; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $208.74M; Long-term Debt, Excluding Current MaturitiesUSD $1.94B; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $2.14B; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $2.14B; Long-Term Debt, Maturity, Year OneUSD $11.84M.
HALOZYME THERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Fair Value Disclosure USD | Debt Instrument, Unamortized Discount USD | Convertible Notes Payable USD | Long-term Debt, Fair Value USD | Debt Instrument, Periodic Payment, Interest USD | Debt Instrument, Convertible, Carrying Amount of Equity Component USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $208.97M | $1.94B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $208.74M | $1.94B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $2.14B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $2.14B | $11.84M | $221.10M | $481.26M | $6.56M | $6.56M | $1.51B | $2.18B | $2.18B | $2.37B | $36.94M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $710.68M | $800.07M | $1.51B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.96B | $14.24M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $1.51B | $1.51B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.63B | $15.90M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.51B | $1.51B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.78B | $17.55M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.51B | $1.51B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.55B | $19.20M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $9.21M | $9.21M | $812.53M | $724.48M | $0.00 | $0.00 | $1.52B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $1.50B | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.66B | $20.85M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.50B | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.57B | $22.48M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $1.50B | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.42B | $24.12M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.50B | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.37B | $25.75M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | (m) | (m) | $9.21M | $9.21M | $9.21M | $812.53M | $724.48M | $0.00 | $1.52B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $1.50B | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.36B | $27.38M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $1.50B | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.33B | $29.00M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $1.49B | $1.49B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.52B | $1.36B | $30.62M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $13.33M | $1.49B | $1.51B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.54B | $1.67B | $32.38M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $22.75M | $9.21M | $9.21M | $9.21M | $812.53M | $724.48M | $1.54B | (m) | (m) | (m) | $1.51B | $1.51B | (m) | (m) |
| 2022-09-30 | $13.31M | $1.49B | $1.50B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.54B | $1.39B | $34.01M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $99.05M | (m) | $1.15B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $895.94M | $884.40M | $17.32M | $878.62M | (m) | (m) | (m) |
| 2022-03-31 | $89.55M | (m) | $788.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $895.94M | $867.32M | $18.29M | $877.64M | (m) | (m) | (m) |
| 2021-12-31 | $89.42M | (m) | $787.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $895.94M | $878.57M | $19.26M | $876.67M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $787.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $94.08M | $2.01M | $2.01M | $2.01M | $2.01M | $805.33M | $895.94M | (m) | (m) | (m) | (m) | $876.67M | (m) | (m) |
| 2021-09-30 | $89.25M | (m) | $786.45M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $895.94M | $893.42M | $20.23M | $875.71M | (m) | (m) | (m) |
| 2021-06-30 | $89.17M | (m) | $785.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $895.94M | $933.30M | $21.20M | $874.74M | (m) | (m) | (m) |
| 2021-03-31 | $89.04M | (m) | $784.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $895.94M | $901.93M | $22.16M | $873.77M | (m) | (m) | (m) |
| 2021-01-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $460.00M | $861.74M | $10.21M | $449.79M | (m) | (m) | (m) |
| 2020-12-31 | $397.23M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $5.80M | (m) |
| 2020-12-31 | (m) | $0.00 | (m) | $465.75M | $0.00 | $0.00 | $0.00 | $0.00 | (m) | $460.00M | (m) | $861.70M | $62.77M | (m) | $397.23M | (m) | (m) |
| 2020-09-30 | $0.00 | (m) | $393.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $591.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $0.00 | (m) | $390.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $585.80M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $2.86M | (m) | $386.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $700.00K | (m) |
| 2019-12-31 | $19.54M | (m) | $383.05M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $461.10M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $383.05M | (m) | $26.10M | $5.75M | $5.75M | $5.75M | $465.75M | (m) | $479.56M | (m) | (m) | $76.97M | (m) | $402.59M | (m) | (m) |
| 2019-11-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $65.60M |
| 2019-09-30 | $54.54M | (m) | $9.31M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $70.88M | (m) | $14.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $86.66M | (m) | $18.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $91.51M | (m) | $34.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $34.87M | (m) | $100.17M | $32.91M | $4.75M | $0.00 | $0.00 | (m) | $127.64M | (m) | (m) | $1.26M | (m) | $126.38M | (m) | (m) |
| 2018-09-30 | $88.52M | (m) | $57.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $86.97M | (m) | $79.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $82.46M | (m) | $102.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $77.21M | (m) | $125.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $125.14M | (m) | $94.12M | $105.76M | $27.31M | $4.75M | $0.00 | (m) | $205.16M | (m) | (m) | $2.81M | (m) | $202.35M | (m) | (m) |
| 2017-09-30 | $61.43M | (m) | $145.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $45.52M | (m) | $165.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $29.60M | (m) | $184.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $17.39M | (m) | $199.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $199.23M | (m) | $37.34M | $94.41M | $105.76M | $24.10M | $4.75M | (m) | $221.15M | (m) | (m) | $4.53M | (m) | $216.62M | (m) | (m) |
| 2016-09-30 | $12.39M | (m) | $199.80M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $3.29M | (m) | $204.85M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $27.42M | (m) | $168.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $21.86M | (m) | $27.97M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $27.97M | (m) | $25.08M | $27.01M | $6.50M | $0.00 | $0.00 | (m) | $50.00M | (m) | (m) | $167.00K | (m) | $49.83M | (m) | (m) |
| 2015-09-30 | $15.70M | (m) | $34.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $9.66M | (m) | $40.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $3.73M | (m) | $45.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $0.00 | (m) | $49.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $49.86M | (m) | $3.77M | $25.08M | $27.01M | $6.50M | $0.00 | (m) | $50.00M | (m) | (m) | $140.00K | (m) | $49.86M | (m) | (m) |
| 2014-09-30 | $10.07M | (m) | $39.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $6.20M | (m) | $43.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $2.40M | (m) | $47.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $49.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $49.77M | (m) | $3.46M | $17.44M | $18.68M | $18.68M | $5.81M | (m) | $50.00M | (m) | (m) | $228.26K | (m) | (m) | (m) | (m) |
| 2013-09-30 | $5.97M | (m) | $23.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $3.64M | (m) | $26.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $1.36M | (m) | $28.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $29.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $29.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $30.00M | (m) | (m) | $338.32K | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |